Exciting News in Rare Disease Research!

Prof Dr Srikumar and his research team have published an illuminating case report and literature review on Gorlin‑Goltz Syndrome in the Journal of Pharmaceutical Research, in collaboration with SRM University (India) and Universitas Negeri Surabaya (Indonesia). Their work brings much‑needed clarity to this rare hereditary cancer syndrome, spotlighting methods that could advance early detection and patient care—a powerful demonstration of SEGi’s research leadership in global health.

Gorlin‑Goltz Syndrome (also known as Gorlin syndrome or basal cell naevus syndrome) is estimated to affect approximately one in 40,000 to 60,000 people globally. Presentation often begins in childhood or adolescence, with lifelong implications: up to 90 % of patients develop recurrent jaw keratocysts, nearly all manifest multiple basal‑cell carcinomas, and serious conditions such as medulloblastoma may arise in around 5–10 % of cases.

Read more at https://university.segi.edu.my/exciting-news-in-rare-disease-research/

This event is organised in support of the following United Nations Sustainable Development Goals (SDG):

SDG 3: Good Health and Well-being

SDG 9: Industry, Innovation and Infrastructure

SDG 17: Partnerships for the Goals